Cortexyme

Cortexyme is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat an underlying cause of Alzheimers and other degenerative diseases. Cortexyme is targeting a specific pathogen found in the brain of Alzheimers patients that causes neurodegeneration and other pathology in animal models. Founded in 2012, the company is headquartered in San Francisco, CA.